vs
Side-by-side financial comparison of COMMUNITY FINANCIAL SYSTEM, INC. (CBU) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
COMMUNITY FINANCIAL SYSTEM, INC. is the larger business by last-quarter revenue ($214.5M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). COMMUNITY FINANCIAL SYSTEM, INC. runs the higher net margin — 26.7% vs 1.6%, a 25.0% gap on every dollar of revenue. On growth, COMMUNITY FINANCIAL SYSTEM, INC. posted the faster year-over-year revenue change (8.7% vs 5.0%). Over the past eight quarters, COMMUNITY FINANCIAL SYSTEM, INC.'s revenue compounded faster (7.9% CAGR vs -0.2%).
Community Health Systems (CHS) is a Fortune 500 company based in Franklin, Tennessee. It was the largest provider of general hospital healthcare services in the United States in terms of number of acute care facilities. In 2014, CHS had around 200 hospitals, but the number had declined to around 85 in 2021.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CBU vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $214.5M | $177.4M |
| Net Profit | $57.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 26.7% | 1.6% |
| Revenue YoY | 8.7% | 5.0% |
| Net Profit YoY | 15.3% | — |
| EPS (diluted) | $1.15 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $214.5M | $177.4M | ||
| Q4 25 | $217.0M | $196.9M | ||
| Q3 25 | $208.1M | $179.5M | ||
| Q2 25 | $200.5M | $181.1M | ||
| Q1 25 | $197.3M | $168.9M | ||
| Q4 24 | $197.4M | $187.3M | ||
| Q3 24 | $190.3M | $168.6M | ||
| Q2 24 | $184.3M | $178.0M |
| Q1 26 | $57.2M | $2.9M | ||
| Q4 25 | $54.4M | — | ||
| Q3 25 | $55.1M | $5.4M | ||
| Q2 25 | $51.3M | $-4.8M | ||
| Q1 25 | $49.6M | $4.8M | ||
| Q4 24 | $49.8M | — | ||
| Q3 24 | $43.9M | $-143.5M | ||
| Q2 24 | $47.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 33.1% | 1.2% | ||
| Q3 25 | 35.2% | 3.5% | ||
| Q2 25 | 32.9% | 4.7% | ||
| Q1 25 | 32.6% | 1.2% | ||
| Q4 24 | 32.7% | 13.2% | ||
| Q3 24 | 30.0% | -82.8% | ||
| Q2 24 | 33.7% | 15.9% |
| Q1 26 | 26.7% | 1.6% | ||
| Q4 25 | 25.1% | — | ||
| Q3 25 | 26.5% | 3.0% | ||
| Q2 25 | 25.6% | -2.7% | ||
| Q1 25 | 25.1% | 2.8% | ||
| Q4 24 | 25.2% | — | ||
| Q3 24 | 23.1% | -85.1% | ||
| Q2 24 | 26.0% | 10.6% |
| Q1 26 | $1.15 | $0.07 | ||
| Q4 25 | $1.03 | $0.05 | ||
| Q3 25 | $1.04 | $0.12 | ||
| Q2 25 | $0.97 | $-0.11 | ||
| Q1 25 | $0.93 | $0.10 | ||
| Q4 24 | $0.94 | $0.38 | ||
| Q3 24 | $0.83 | $-3.11 | ||
| Q2 24 | $0.91 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $572.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.0B | $653.9M |
| Total Assets | $17.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $572.2M | $144.3M | ||
| Q4 25 | $301.8M | $238.4M | ||
| Q3 25 | $245.2M | $246.3M | ||
| Q2 25 | $237.2M | $445.9M | ||
| Q1 25 | $518.0M | $493.6M | ||
| Q4 24 | $197.0M | $484.6M | ||
| Q3 24 | $346.1M | $453.8M | ||
| Q2 24 | $201.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $990.2M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.0B | $653.9M | ||
| Q4 25 | $2.0B | $693.1M | ||
| Q3 25 | $1.9B | $727.2M | ||
| Q2 25 | $1.9B | $757.8M | ||
| Q1 25 | $1.8B | $798.5M | ||
| Q4 24 | $1.8B | $778.3M | ||
| Q3 24 | $1.8B | $749.6M | ||
| Q2 24 | $1.7B | $879.3M |
| Q1 26 | $17.5B | $1.2B | ||
| Q4 25 | $17.3B | $1.3B | ||
| Q3 25 | $17.0B | $1.3B | ||
| Q2 25 | $16.7B | $1.5B | ||
| Q1 25 | $16.8B | $1.6B | ||
| Q4 24 | $16.4B | $1.6B | ||
| Q3 24 | $16.4B | $1.5B | ||
| Q2 24 | $15.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.56× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBU
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
